Quethera has a technology to express therapeutic proteins in the retinal cells of glaucoma patients utilizing recombinant adeno-associated viral vector system (rAAV). Glaucoma is a disease in which damage of the optic nerve progresses, and in many cases is accompanied by an increase in intraocular pressure. It was confirmed in a preclinical study conducted by Quethera that the survival rate of retinal ganglion cells improved by using rAAV-based gene therapy.
Astellas news release, August 16, 2018
Astellas acquires British Quethera Inc. to develop gene therapy for glaucoma